Chapter 32: Substance Use Disorders I: Basic Considerations

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know,

usually when we talk about a medical diagnosis, there's this like underlying expectation of precision.

Right.

It feels kind of like engineering.

Right.

Yeah.

Like it's very black and white.

Exactly.

You break your arm, the x -ray shows that jagged white line, and the clinician just points at the screen and says, you know, there it is.

It's binary.

I mean, it is broken or it is not broken.

And we naturally gravitate toward things that are visible like that.

Because it makes the treatment plan obvious.

Right.

Exactly.

It's easy to categorize.

But then you step into the world of substance use and addiction, and suddenly that x -ray machine is just totally useless.

We're looking at a diagnostic landscape that is incredibly murky.

Oh, absolutely.

It is the absolute definition of diagnostic muddy waters.

Especially if you're an advanced practice nursing or physician assistant student, you know, trying to prep for clinicals or scaring down a massive pharmacology exam.

Yeah.

You have to figure out where the social science ends and the hard neurobiology begins,

which is exactly why we're doing this deep dive today.

Right.

So for you listening right now, consider this a dedicated one -on -one clinical tutoring session.

We are diving into Chapter 32 of Lynn's Pharmacotherapeutics, the third edition.

Yeah.

Specifically looking at substance use disorders to sick, which covers the basic considerations.

We're going to translate all of that dense pathophysiology into a very clear clinical decision -making framework.

Because the goal isn't just to memorize the what of addiction, but to truly understand the why.

And to get there, we need a precise shared vocabulary.

Which means we start right where the chapter starts defining drug misuse.

Right.

But the deeper you look into the text, you realize that drug misuse is largely, well, culturally defined.

It's not this fixed biological constant across time and space.

No, not at all.

We see that definition shift depending on where and when you look.

I mean, take LSD, lysergic acid, diacylamide.

Oh, yeah.

That's a great example.

Right.

When Americans first started experimenting with psychedelics, it was actually legal.

It wasn't universally condemned at all.

It only became illegal and medically labeled as misuse when, you know, the consumption became widespread and the whole societal posture changed.

Exactly.

And we see this geographically too.

In many societies, moderate consumption of alcohol is perfectly acceptable.

It's just a normal part of dinner.

But in some Muslim societies, any ingestion of alcohol is considered misuse.

So distinguishing between culturally acceptable drug use and drug use that constitutes misuse it really leans heavily into sociology.

Which means, as a prescribing clinician,

your focus has to pivot away from all that cultural noise.

You have to look at the hard science.

Right.

You pivot strictly toward the pharmacologic properties and the physiological realities of the substances themselves.

We have to strip away the cultural bias to see what the drug is actually doing to the body at a cellular level.

And that requires locking down some very specific clinical definitions,

starting with tolerance.

Yeah.

So tolerance results from regular drug use.

It's a physiological state where a particular dose elicits a smaller response than it did with the initial use.

Because the body's receptors are desensitizing, right?

So the patient needs higher and higher doses to get the desired effect.

Simple enough.

Simple enough.

Yeah.

But then there is cross -tolerance.

And this usually develops among drugs within a particular pharmacologic class, not between drugs in different classes.

OK.

Let's unpack this with an analogy.

It's kind of like building an immunity to a specific genre of movies.

OK.

I like where this is going.

Like, if you watch a hundred action movies, you build a tolerance to car chases.

It takes bigger and bigger explosions to actually thrill you.

Right.

Yeah.

Cross -tolerance means you're immune to action thrillers, too.

But it doesn't mean you have a tolerance for romantic comedies or horror films.

That's a perfect way to look at it.

Yeah.

Just like heroin tolerance doesn't give you tolerance to a completely different class, like a CNS depressant or nicotine.

Right.

And this distinction is vital for patient safety.

If a patient has a tolerance to one opioid, like heroin,

they will have cross -tolerance to other opioids, like morphine.

Because their opioid receptors have adapted to the whole family of drugs.

Exactly.

But clinically,

that means a patient tolerant to massive, otherwise lethal doses of opioids can still easily overdose if given a standard dose of a completely different drug, like a barbiturate.

Wow.

Right.

Because their body has zero adapted immunity to the respiratory depression caused by that new drug class.

Exactly.

So moving from tolerance, we have to evaluate dependence, which is split into psychological and physical categories.

Right.

So psychological dependence is that intense subjective need for a drug, like a really severe cognitive craving.

But physical dependence is a completely different mechanism.

That is defined as a state where an abstinence syndrome, withdrawal syndrome will occur if the drug use is suddenly discontinued.

And that's the result of actual neuro -adaptive processes in the brain from prolonged drug exposure, right?

The body has essentially established a new artificial homeostasis.

Right.

And similarly to cross -tolerance, we also see cross -dependence.

Okay.

So what does that look like?

Well, this is the ability of one drug to support physical dependence on another drug.

If drug A and drug B share cross -dependence, taking drug A will prevent withdrawal in a patient physically dependent on drug B.

Oh, so we utilize this principle in clinical practice all the time, right?

Like using methadone to prevent withdrawal in a patient dependent on heroin.

Spot on.

Which brings up the withdrawal syndrome itself.

And there's a really helpful clinical rule of thumb here.

Yeah, that the constellation of signs and symptoms during withdrawal are almost always the exact opposite of the effects the drug produced before it was withdrawn.

Because the body is rebounding.

I mean, if a patient is taking a CNS depressant long -term, the body upregulates its excitatory pathways to try and stay awake and functional.

Ah, so it's fighting against the depressant.

Exactly.

So when you suddenly remove the depressant, those excitatory pathways are left completely unopposed.

So during withdrawal, you don't look for depressed vitals.

You look for the opposite.

You look for CNS excitation.

Right.

Tachycardia, severe anxiety, and potentially even life -threatening seizures.

Wait, hold on.

I need to pause here because this trips up a lot of people in clinical rotation.

What's the hangup?

You're telling me a cancer patient can be completely physically dependent on high -dose fentanyl.

They have massive tolerance.

They will go into severe withdrawal if the patch is removed.

But clinically, we do not call that an addiction.

Correct.

We do not.

We don't diagnose them with a substance use disorder.

How does that make sense?

If we connect this to the bigger picture, it comes down to distinguishing between a normal physiological adaptation and a behavioral pathology.

Physical dependence is not the same as a substance use disorder.

The American Psychiatric Association defines SUD as a cluster of cognitive, behavioral, and physiological symptoms, indicating that the individual continues using this substance despite significant problems.

Ah, okay.

So for that individual with terminal cancer on long -term opioids, their life is not disrupted by compulsive, problematic behavior trying to seek the drug.

Exactly.

The medication is actually what allows their life to remain functional and comfortable.

That makes total sense.

Or consider patients taking phenobarbital to control severe seizure disorders.

I mean, they develop profound physical dependence over time.

Right, but they aren't robbing pharmacies or destroying their relationships to get more phenobarbital.

Exactly.

They don't carry out addictive behavior, so they do not have an SUD.

Physical dependence certainly contributes to the difficulty of quitting a drug, but it is neither necessary nor sufficient for an addiction diagnosis.

Okay, so if physical dependence isn't the primary driver of addiction,

why does someone progress from experimental use to that compulsive, harmful use?

Like what actually pushes a patient across that line?

We have to look at the reinforcing properties of drugs themselves.

In animal laboratory studies, rats or monkeys will self -administer almost all the drugs abused by humans.

Opioids, barbiturates, alcohol, cocaine.

Yeah, amphetamines too.

They will press a lever to self -administer these drugs in preference to eating, drinking, and sex.

Wow.

They will literally choose the drug over survival until they die from starvation or dehydration, which is just a terrifying realization.

It really is.

And it proves that pre -existing psychopathology, like trauma history or a personality disorder, is not strictly required for drug use to develop.

The profound reduction of stress or the intense pleasure the drug provides is powerful enough to hijack the brain's priorities all on its own.

Exactly.

Though, while the pharmacology alone is powerful,

individual vulnerability plays a massive role.

Some people are simply more prone to misusing drugs.

Right, so psychological traits like impulsivity or a low tolerance for frustration.

Yes, or underlying depressive and anxiety disorders.

Those significantly increase risk.

Very often, drug use begins as a desperate attempt at self -medication to relieve intense emotional discomfort.

We also know genetics play a role too, right?

Particularly an inherited predisposition to alcohol use disorder.

Absolutely.

And then you add social factors and availability into the mix.

I mean, initial drug experiences are rarely pleasant.

Yeah, most people cough and feel sick during their first cigarette.

And initial heroin use causes intense nausea and vomiting.

Right, so it is often peer pressure and the desire for social approval that compels someone to push through that initial sickness long enough for tolerance to develop.

And abuse always flourishes where drugs are easy to get.

Which is a reality health care professionals must internalize.

Ready availability is a major driver of the high rates of addiction observed among nurses, pharmacists and physicians.

Right, because you're working in environments where highly reinforcing substances are mere feet away.

Exactly.

So we understand the behaviors and the risk factors, but to really grasp why patients compulsively use despite losing their careers, their families and their health, we have to look under the hood.

We have to look at the structural neurobiology of addiction.

Right, because the transition from voluntary to compulsive use happens because the brain's circuitry is physically changing.

Yes, we are specifically talking about the reward circuit.

This pathway originates in the ventral tegmental area of the midbrain and projects to the nucleus accumbens.

And its major neurotransmitter is dopamine.

Exactly.

Under normal circumstances, this system rewards us for behaviors essential for survival,

like eating a nutritious meal by releasing a measured amount of dopamine.

It tells the brain, that was good, do it again.

But addictive drugs are incredibly effective at hijacking this specific circuit.

I mean, the amount of dopamine released by addictive drugs can be two to ten times the amount released by natural stimuli.

It's a massive unnatural flood of dopamine that the brain was never evolved to handle.

So in response to this excessive activation, the brain attempts to protect itself, right?

It tries to restore balance through a process called downregulation.

Yes.

At the synaptic level, the brain starts producing less of its own endogenous dopamine, and it actively reduces the number of dopamine receptors available on the postsynaptic neurons.

It's basically trying to turn the volume down on the drugs' effects.

Exactly.

Here's where it gets really interesting.

It's like listening to music at maximum volume for months.

Your brain eventually blows out its own internal speakers.

That's the downregulation, just to protect itself from the noise.

That's a great way to visualize it.

But the tragedy is, when you finally turn off the music, when the drug use stops, those speakers are so damaged that you can't even hear a normal conversation.

Right.

Natural stimuli like a good meal, a hug from a loved one, a beautiful day, they release normal amounts of dopamine, but it's no longer enough to activate that downregulated reward circuit.

So when those internal speakers are blown out, the clinical result is that the patient is left feeling profoundly flat, lifeless, and depressed.

And this isn't just a psychological mood swing or a lack of willpower.

It is a structural neurobiological deficit.

They physically cannot experience joy.

Wow.

However, the most critical patient education point you can provide is that this neural remodeling is not permanent.

With sustained abstinence, the brain gradually reverses the downregulation and heals.

And that reversibility is the beacon of hope in treating SED.

But since that healing takes months, or even years, how do clinicians actually approach treatment while the patient's brain is in that vulnerable state?

Well, we rely on frameworks like the National Institute on Drug Abuse or MINI -DAY guidelines.

They outline principles of drug addiction treatment that center on the premise that SED is a highly treatable disease of the brain.

With comprehensive therapy,

between 40 % and 60 % of individuals can significantly reduce their drug use.

But the reality of chronic disease management applies here.

Addiction is a chronic relapsing illness.

The guidelines are very clear that periods of treatment -induced abstinence will likely be followed by relapse.

They will, yeah.

So what does this all mean for clinical expectations?

If a patient relapses, it feels like human nature to view that as a failure of the therapy or a failure of the patient's willpower.

And that is a trap clinicians must actively avoid.

If we view SUD through the same clinical lens as other chronic diseases,

a relapse does not equal treatment failure.

Think about a patient with asthma or essential hypertension.

If they have a severe asthma exacerbation or their blood pressure spikes, we don't accuse them of failing.

No, we look at the data, we look at their triggers, and we adjust the medication.

Exactly.

A relapse in SUD simply indicates that another treatment episode is numbed or the current approach needs modification.

And remaining in treatment for an adequate amount of time is absolutely critical for that structural brain healing to occur.

Right.

Most patients require at least three months of continuous treatment to significantly reduce or stop drug use.

And we need to evaluate the goals of that treatment, too.

Ideally, complete cessation is the goal.

But we also have to embrace harm reduction.

Yes.

A shift from compulsive use to moderate use can absolutely be considered a clinical success if it significantly improves the patient's physical health, productivity, and social behavior.

However, clinical experience issues a very stark warning here.

For certain substances, nothing short of total abstinence is effective.

That's true.

Individuals who misuse cigarettes, alcohol, and opioids are very rarely capable of sustaining moderate use over the long term.

The brain's pathways are just too deeply carved.

Which requires treating the whole person.

You have to address medical, psychological, social, vocational, and legal problems simultaneously.

Yes.

And an incredibly important point for prescribing clinicians is understanding the role of medically assisted detoxification.

Detox is only the very first stage of treatment.

Right.

By itself, it does almost nothing to change long -term drug use.

Detox merely manages the acute physical withdrawal syndrome so the patient doesn't suffer severe physiological rebound effects.

It clears the substance from the system safely.

But remember, clearing the drug doesn't instantly fix those down -regulated dopamine receptors we talked about.

Exactly.

That is why behavioral therapy and medication -assisted treatment like using partial agonists to stabilize cravings without producing a high ward must immediately follow detox to do the real work of recovery.

And if you are going to be prescribing or administering these therapies or managing patients taking controlled substances for other conditions, you absolutely must understand the legal framework governing them.

Which brings us to the Controlled Substances Act, or the CSA.

Passed in 1970, this is the principal federal legislation addressing drug abuse, and it's enforced by the DEA.

Right.

And the overarching goal of the CSA is to prevent drugs from legitimate medical sources from being diverted to individuals with an SUD.

To accomplish this, the CSA mandates incredibly strict record -keeping.

Every time a controlled substance is manufactured, purchased, or dispensed, it must be recorded.

Providers and hospitals must maintain a secure inventory and report to the DEA every two years.

And the core of this system is the DEA schedules.

Every drug regulated under the CSA is assigned to one of five categories.

Schedule I through Schedule V.

And this assignment is based entirely on the drug's abuse potential and its potential for causing physical or psychological dependence, right?

Correct.

So, Schedule I drugs have a high potential for abuse and absolutely no approved medical use in the United States.

This includes substances like heroin, LSD, and marijuana.

Right.

And because there is no accepted medical use federally, you cannot write a prescription for a Schedule I drug.

Okay.

Then you have Schedule II.

These drugs also have a very high potential for abuse and dependence, but they do have approved legitimate medical applications.

These are the heavy hitters.

We're talking about potent opioids like morphine, fentanyl, oxycodone, and methadone.

Right.

And it also includes psychostimulants like amphetamine and methylphenidate used for ADHD and certain barbiturates like pentobarbital.

Then as we move down to Schedules IV and V, the abuse and dependence liabilities progressively decrease.

Okay.

So, Schedule III includes drugs like buprenorphine, ketamine, and anabolic steroids.

And Schedule IV is heavily populated by the benzodiazepines like alprozolam, diazepam, lorazepam, as well as sleep aids like zulpidem.

Wait, question.

Why are benzodiazepines down in Schedule IV while barbiturates are way up in Schedule II?

I mean, they're both CNS depressants used for anxiety and sleep?

It comes down to their safety profiles and mechanism of action.

Enzodiazepines have a built -in sealing effect on respiratory depression.

Oh, I see.

Yeah.

So even if a patient takes a massive dose of a benzo alone, it is very difficult to cause fatal respiratory arrest.

Barbiturates do not have that sealing effect.

So they will just continue to depress the central nervous system until the patient stops breathing entirely.

Exactly.

Because barbiturates are intrinsically more lethal in overdose,

their schedule reflects a much tighter level of restriction.

That makes total sense.

Finally, we have Schedule V, which has the lowest abuse potential of the controlled substances.

Right.

This includes drugs like pregabalin and certain cough or antidiarrheal preparations containing very small amounts of opioids like diphenoxylate combined with atropine.

And knowing these schedules dictates exactly how you are legally allowed to prescribe.

Like for Schedule II drugs, the rules are unforgiving.

Extremely unforgiving.

Prescriptions must be typed or filled out in ink and physically signed or submitted via a highly secure approved electronic prescribing procedure.

So as a clinician, if a patient calls on a Friday night in severe pain, can you call in a Schedule II prescription over the phone to the pharmacy?

Only in a true, documented medical emergency.

And even then, a hard copywritten prescription must follow within 72 hours.

Wow.

Furthermore, prescriptions for Schedule II drugs absolutely cannot be refilled.

Zero refills.

If the patient needs more, they need a completely new prescription.

However, a provider can write multiple prescriptions on the same day for the same patient for the same Schedule II drug with instructions to fill them sequentially on specific future dates.

Yes.

That is allowed.

Now,

for Schedules III and IV, the rules relax slightly.

These prescriptions can be oral, written, or electronic without that emergency requirement.

And they can be refilled up to five times, right?

But those refills must be dispensed within six months of the original order date.

Exactly.

After six months or after five refills, the prescription is dead.

And Schedule V mostly follows those same rules for Schedules III and IV.

Interestingly, some Schedule V drugs can actually be dispensed by a pharmacist without a prescription at all, provided certain strict conditions are met.

Right.

Like, the recipient must be at least 18.

The pharmacist must record the transaction.

And state laws must actually allow it.

Which brings up a very common clinical dilemma.

As a prescribing clinician, what happens when state and federal laws clash?

Like, if my specific state allows a prescribing practice,

say, dispensing medical marijuana or dispensing a Schedule V without a prescription, but the federal DEA law forbids it, who wins?

This is the golden rule of drug enforcement for clinicians.

Whenever state and federal laws clash,

you must always follow the more restrictive law.

So if the state says yes, but the federal law says no, the answer is no.

And if the federal law says yes, but the state law says no, the answer is still no.

You always default to the strictest regulation to protect your license and, more importantly, to protect your patients.

Man, we have covered a massive amount of clinical ground today.

We started with understanding how fluid cultural definitions of misuse have to give way to strict behavior -based clinical diagnoses of substance use disorder.

Right.

And we explored the mechanisms behind physiological dependence and withdrawal, recognizing that a rebounding central nervous system produces symptoms completely opposite to the drug's initial effects.

We looked at the dopamine -driven neurobiology, detailing how massive neurotransmitter floods cause the structural downregulation of the reward circuit.

Which fuels compulsive use and really explains the profound depressive state of early recovery.

We also framed treatment through chronic disease management, you know, accepting the reality of relapse without viewing it as clinical failure.

And finally, we detailed the strict DEA schedules and prescribing rules you must respect to practice safely.

It's a profoundly complex intersection of social behavior, molecular biology, and federal law.

And I want to leave you with a final thought to mull over as you continue your clinical training.

Yeah, think about this.

We established early on that misuse is heavily culturally defined.

Yet, we also know definitively that these drugs cause objective, measurable changes in the brain's reward circuits via dopamine downregulation.

At hard biology.

Right.

So as our society continues to rapidly shift its cultural and legal acceptance of substances,

I mean, just look at the rapidly shifting landscape of cannabis and psychedelics right now.

How will our clinical definition of a substance -related problem have to evolve to keep up with both the shifting sociology and the rigid hard biology?

That is the defining clinical question for the next generation of advanced practice nurses and physician assistants.

Absolutely.

We want to issue a warm, supportive thank you for your dedication to learning this material.

The line between treating pain and managing addiction is thin and your future patients are incredibly lucky to have clinicians willing to understand the science behind it.

On behalf of the last minute lecture team, thanks for joining us.

Keep studying and we'll see you next time.